Rufinamide is an antiepileptic drug (AED) used primarily for the treatment of Lennox-Gastaut syndrome (LGS), a severe form of childhood-onset epilepsy. It is typically prescribed as an adjunctive therapy and is known by the brand name Banzel® in the U.S. and Inovelon® in Europe.
Rufinamide works by modulating sodium channel activity in the brain, prolonging the inactive state of voltage-gated sodium channels. This reduces neuronal hyperexcitability, thereby preventing seizures.
It is administered orally, either as a tablet or oral suspension, and is generally taken with food to enhance absorption.
Parent: Rufinamide
Impurities in rufinamide may originate from synthetic pathways, degradation during storage, or formulation components, and are strictly regulated to ensure product safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Rufinamide is used as an add-on treatment for seizures associated with:
Common side effects include:
Serious but rare side effects:
